Pexmetinib (formerly ARRY614; ARRY-614) is a novel, potent, orally bioavailable, and dual inhibitor of p38 mitogen-activated protein kinase and Tie2 kinases with potential anti-inflammatory, anti-cancer and antiangiogenic activity.

R1487 HCl is a novel, potent, orally bioavailable, and highly selective inhibitor of p38α mitogen-activated protein kinase.

Losmapimod (formerly known as GSK-AHAB; GSK AHAB; GW856553, SB856553 or GW-856553X) is a novel, selective, potent, and orally bioavailable inhibitor of p38 MAPK (p38 mitogen-activated protein kinases) with potential antidepressant, anti-hypertensive and anti-inflammatory activity.

SKF-86002 is a novel and potent inhibitor of the p38 MAP kinase with IC50 of 0.5-1 uM; it inhibits LPS-induced IL-1 and TNF-α production in human monocytes with IC50 of 1 μM.